Faculty
 
 
 
Karen Van Nuys, Ph.D.

Karen Van Nuys, Ph.D.

Research Assistant Professor, Sol Price School of Public Policy






Dr. Karen Van Nuys is a Research Assistant Professor and the Executive Director of the Value of Life Sciences Innovation Project at the USC Price School of Public Policy and in the Schaeffer Center for Health Policy & Economics. Her recent research focuses on the social value of novel therapies for heart failure and hepatitis C, the flow of funds in the pharmaceutical distribution chain, and the impact of commercial practices such as copay coupons and copay clawbacks on the utilization and cost of prescription drugs.  Her work has been published in leading journals in economics, medicine, finance, and health policy.  

Dr. Van Nuys has held positions across both industry and academia, including as Principal and Priority Service Offering Director at Booz Allen Hamilton, Senior Research Economist at Precision Health Economics, National Fellow at the Hoover Institution, and an Assistant Professor at the Simon School of Business at the University of Rochester.  She has consulted with Fortune 50 companies ranging from insurance providers and life sciences companies to automotive manufacturers and media conglomerates.  She received her PhD in Economics from Stanford University, and her MA and BA degrees from the University of California, San Diego.

Recent Publications
Frequency and Magnitude of Copayments Exceeding Prescription Drug Costs
(with G. Joyce, R. Ribero and D. Goldman), JAMA 319(10): 1045-1047; 2018.

Overpaying for Prescription Drugs:  The Copay Clawback Phenomenon
(with G. Joyce, R. Ribero and D. Goldman), USC Schaeffer Whitepaper 2018.

A Perspective on Prescription Drug Copayment Coupons
(with G. Joyce, R. Ribero and D. Goldman), USC Schaeffer Whitepaper 2018.

Innovation in Heart Failure Treatment: Life Expectancy, Disability, and Health Disparities
(with Z. Xie, B. Tysinger, M. Hlatky and D. Goldman), JACC-Heart Failure DOI:  10.1016/j.jchf.2017.12.006, 2018.

Reining in Pharmaceutical Costs (with I. Spatz and D. Goldman), USC Schaeffer Whitepaper 2017.

The Flow of Money Through the Pharmaceutical Supply Chain
(with N. Sood, T. Shih, and D. Goldman), USC Schaeffer Whitepaper 2017.

Economic Study of the Value of Expanding HCV treatment capacity in Germany (with U. Sbarigia, D. Wirth, C. Huber, R. Brookmeyer, J. Stahmeyer and C. Krauth). BMJ Open Gastro DOI: 10.1136/bmjgast-2016-000130, 2017.

Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity is a Concern (with R. Brookmeyer, J. Chou, D. Dreyfus, D. Dieterich and D. Goldman), Health Affairs 34(10):1666-1674, 2015.

Aligning Incentives to Fulfil the Promise of Personalized Medicine (with V. Dzau, G. Ginsburg, D. Agus and D. Goldman), The Lancet 385(9982): 2118-2119, 2015.

Reforming Medicare’s Dialysis Payment Policies:  Implications for Patients with Secondary Hyperparathyroidism (with C. Gupta, G. Chertow, M. Linthicum, V. Belozeroff, D. Quarles and D. Lakdawalla), Health Services Research 49(6): 1925-1943, 2014.

The Association Between Employee Obesity and Employer Costs: Evidence From a Panel of U.S. Employers (with D. Globe, D. Ng-Mak, H. Cheung, J. Sullivan and D. Goldman), American Journal of Health Promotion 28(5):277-88, 2014.

Strategic Impact of a New Academic Endocrine Surgery Program (with J. Wiseman, P. Ituarte, R. Hwang, J. Pasternak, I. Safir, and M. Yeh), Ann Surg Oncol 18(8): 2260-2264, 2011. 

Burden of Illness of Diabetic Macular Edema: Literature Review (with E. Chen, M. Looman, M. Laouri, M. Gallagher, D. Lakdawalla, and J. Fortuny), Current Medical Research and Opinion 26:7, 1587-1597, DOI: 10.1185/03007995.2010.482503, 2010.